Split intein-mediated protein trans-splicing to express large dystrophins

• 成果类型: Article
• 署名作者: Tasfaout, Hichem; Halbert, Christine L.; McMillen, Timothy S.; Allen, James M.; Reyes, Theodore R.; Flint, Galina V.; Grimm, Dirk; Hauschka, Stephen D.; Regnier, Michael; Chamberlain, Jeffrey S.
• 署名单位: University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; German Center for Infection Research; German Centre for Cardiovascular Research; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle
• 刊物名称: Nature
• ISSN/ISSBN: 0028-6456
• DOI: 10.1038/s41586-024-07710-8
• 发表日期: 2024-08-01
• 页码: 192-+
• 关键词: mdx mice; gene-therapy; life-span; muscle; skeletal; mouse; ORGANIZATION; deletions; sequence; dna

摘要

Gene replacement using adeno-associated virus (AAV) vectors is a promising therapeutic approach for many diseases(1,2). However, this therapeutic modality is challenged by the packaging capacity of AAVs (approximately 4.7 kilobases)(3), limiting its application for disorders involving large coding sequences, such as Duchenne muscular dystrophy, with a 14 kilobase messenger RNA. Here we developed a new method for expressing large dystrophins by utilizing the protein trans-splicing mechanism mediated by split inteins. We identified several split intein pairs that efficiently join two or three fragments to generate a large midi-dystrophin or the full-length protein. We show that delivery of two or three AAVs into dystrophic mice results in robust expression of large dystrophins and significant physiological improvements compared with micro-dystrophins. Moreover, using the potent myotropic AAVMYO(4), we demonstrate that low total doses (2 x 10(13) viral genomes per kg) are sufficient to express large dystrophins in striated muscles body-wide with significant physiological corrections in dystrophic mice. Our data show a clear functional superiority of large dystrophins over micro-dystrophins that are being tested in clinical trials. This method could benefit many patients with Duchenne or Becker muscular dystrophy, regardless of genotype, and could be adapted to numerous other disorders caused by mutations in large genes that exceed the AAV capacity.